Literature DB >> 9041667

Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults.

D L Krah1, I Cho, T Schofield, R W Ellis.   

Abstract

A comparison was made of antibody responses generated to live varicella (Oka/Merck) vaccine (Varivax) produced during three different manufacturing campaigns to evaluate the quality of the antibody responses and demonstrate consistency of the manufacturing process. Anti-varicella zoster virus (VZV) antibody titers were measured by an enhanced neutralization assay and VZV glycoprotein-based enzyme-linked immunosorbent assay (gpELISA). For sera taken from children who had received one dose of vaccine an excellent linear concordance in titers was observed between the two assays. Sera from adults who had received two doses demonstrated continuing increased neutralization at high gpELISA titers. The immunogenicity measured by the two assays demonstrates that the overall performance of the vaccine was very similar over the three production series.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041667     DOI: 10.1016/s0264-410x(96)00107-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

Review 1.  Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.

Authors:  Kristine Macartney; Anita Heywood; Peter McIntyre
Journal:  Cochrane Database Syst Rev       Date:  2014-06-23

2.  Seroepidemiologic survey of varicella-zoster virus in korean adults using glycoprotein enzyme immuno assay and fluorescent antibody to membrane antigen test.

Authors:  Yun Hwa Kim; Ji Young Hwang; Kyung Min Lee; Jin Hee Choi; Tae Yoon Lee; Jong Soo Choi; Ho Sun Park
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

3.  Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.

Authors:  Timo Vesikari; Roland Hardt; Hans C Rümke; Giancarlo Icardi; Jordi Montero; Stéphane Thomas; Christine Sadorge; Anne Fiquet
Journal:  Hum Vaccin Immunother       Date:  2013-01-14       Impact factor: 3.452

4.  Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.

Authors:  Robert Arnou; Anne Fiquet; Stéphane Thomas; Christine Sadorge
Journal:  Hum Vaccin       Date:  2011-10-01

5.  High-level cellular and humoral immune responses in Guinea pigs immunized intradermally with a heat-inactivated varicella-zoster virus vaccine.

Authors:  Julia Sarkadi; Mate Jankovics; Kinga Fodor; Zoltan Kis; Maria Takacs; Ildiko Visontai; Istvan Jankovics; Eva Gonczol
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

6.  Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test.

Authors:  Andreas Sauerbrei; Anna Schäfler; Jörg Hofmann; Michael Schacke; Bernd Gruhn; Peter Wutzler
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

Review 7.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

8.  A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Authors:  Maria G Vizoso Pinto; Klaus-Ingmar Pfrepper; Tobias Janke; Christina Noelting; Michaela Sander; Angelika Lueking; Juergen Haas; Hans Nitschko; Gundula Jaeger; Armin Baiker
Journal:  Virol J       Date:  2010-07-20       Impact factor: 4.099

9.  Complete DNA sequences of two oka strain varicella-zoster virus genomes.

Authors:  Sueli L Tillieux; Wendy S Halsey; Elizabeth S Thomas; John J Voycik; Ganesh M Sathe; Ventzislav Vassilev
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

10.  Primary vaccine failure after 1 dose of varicella vaccine in healthy children.

Authors:  David E Michalik; Sharon P Steinberg; Philip S Larussa; Kathryn M Edwards; Peter F Wright; Ann M Arvin; Haley A Gans; Anne A Gershon
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.